(Q34568695)

3 August 2017

1 reference

title

Interferon-alpha in tumor immunity and immunotherapy (English)

1 reference

3 August 2017

1 reference

Enrico Proietti

3

1 reference

ORCID Public Data File 2021

author name string

Filippo Belardelli

series ordinal

1

1 reference

PubMed ID

11900988

3 August 2017

Maria Ferrantini

series ordinal

2

1 reference

PubMed ID

11900988

3 August 2017

John M Kirkwood

series ordinal

4

1 reference

3 August 2017

1 April 2002

1 reference

Cytokine and Growth Factor Reviews

3 August 2017

1 reference

3 August 2017

13

1 reference

3 August 2017

119-134

1 reference

3 August 2017

2

1 reference

Cytokine therapeutics: lessons from interferon alpha

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Role of interferons and other cytokines in the regulation of the immune response.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

The type I interferon receptor: structure, function, and evolution of a family business.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

The neglected role of type I interferon in the T-cell response: implications for its clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

A new American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

The orderly progression of melanoma nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Induction of TH1 and TH2 responses: a key role for the 'natural' immune response?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Selective expression of an interleukin-12 receptor component by human T helper 1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Induction of bystander T cell proliferation by viruses and type I interferon in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Type I interferon-mediated stimulation of T cells by CpG DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Type I interferons keep activated T cells alive

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

The dendritic cell system and its role in immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Origin, maturation and antigen presenting function of dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

The nature of the principal type 1 interferon-producing cells in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. IV. Definition of optimal treatment regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. VI. Adjuvant therapy after surgery in the inhibition of liver and spleen metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Mechanism of the Antitumour Effect of Interferon in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN alpha/beta therapy of Friend erythroleukemia visceral metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Elusive interferon alpha producers nailed down

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Cytokines, tumour-cell death and immunogenicity: a question of choice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

1 reference

7 January 2021

Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Murine interferon-alpha1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-alpha/beta therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-alpha 1 and herpes simplex thymidine kinase followed by ganciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-alpha and HSVtk: perspectives for the generation of cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon alpha gene therapy in combination with adoptive chemoimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Treatment of leukemia with fibroblast-mediated interferon-alpha gene therapy alone or in combination with doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Nonviral interferon alpha gene therapy inhibits growth of established tumors by eliciting a systemic immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Interferons in the therapy of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

The Philadelphia chromosome translocation. A paradigm for understanding leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Role of interferon-alpha and clonally expanded T cells in the immunotherapy of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-α

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Recombinant interferon alpha can induce rearrangement of T-cell antigen receptor alpha-chain genes and maturation to cytotoxicity in T-lymphocyte clones in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Functional role of type I and type II interferons in antiviral defense

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th1-type cytokine production and improves the proliferative response to recall antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6101%2801%2900022-3

7 January 2021

10.1016/S1359-6101(01)00022-3

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11900988